David M. Stack Joins Board of Directors of Molecular Insight Pharmaceuticals, Inc.CAMBRIDGE, Mass. -- Molecular Insight Pharmaceuticals, Inc. today announced that David M. Stack has joined the company's Board of Directors. Mr. Stack brings over 25 years of experience in marketing, sales and commercialization at companies in the biotechnology and pharmaceutical sectors, including Roche Labs, Innovex, The Medicines Company and MPM MPM Multi-Processing Module (Apache) MPM Manufacturing Process Management MPM Milwaukee Public Museum MPM MMW (Millimeter Wave) Power Module MPM Master of Project Management (degree) Capital. Mr. Stack is currently Executive Partner at MPM Capital's MPM BioVentures IV Fund. Previously, he served as President and Chief Executive Officer of The Medicines Company, which specializes in acute care pharmaceuticals. Prior to The Medicines Company, he served as President of Innovex Inc. Previously, Mr. Stack served as Vice President of Business Development at Immunomedics, and before that he held a variety of positions of increasing responsibility at Roche Laboratories, most recently as Director, Business Development and Planning, Infectious Disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. , Oncology, and Virology virology, study of viruses and their role in disease. Many viruses, such as animal RNA viruses and viruses that infect bacteria, or bacteriophages, have become useful laboratory tools in genetic studies and in work on the cellular metabolic control of gene expression . Mr. Stack holds a B.S. degree in Biology from Siena College and a B.S. degree in Pharmacy from the Albany College of Pharmacy Albany College of Pharmacy is a pharmaceutical college in Albany, New York, United States. It was founded in 1881 as the Department of Pharmacy of Union University. Presently, it is one of the only independent schools of pharmacy in the United States. . About Molecular Insight Pharmaceuticals, Inc. Molecular Insight Pharmaceuticals is a biopharmaceutical company focused on the research, development and commercialization of innovative molecular imaging pharmaceuticals and targeted radiotherapeutics. The company's product candidates target markets with significant unmet needs in cardiology, oncology, and neurology. Molecular Insight's lead product candidate, Zemiva(TM) (iodofiltic acid I 123) is in development as a molecular imaging pharmaceutical for the diagnosis of insufficient blood flow to the heart, or cardiac ischemia. The company's second lead product candidate, Azedra(TM) (Ultratrace(TM) MIBG MIBG Metaiodobenzylguanidine ), is in development for the diagnosis and treatment of neuroendocrine tumors Neuroendocrine Tumors Definition Neuroendocrine tumor refers to the type of cell that a tumor grows from rather than where that tumor is located. . Molecular Insight Pharmaceuticals is based in Cambridge, Massachusetts. The company's website is: www.molecularinsight.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion